263 related articles for article (PubMed ID: 16413398)
1. Myeloablative and immunosuppressive properties of treosulfan in mice.
Sjöö F; Hassan Z; Abedi-Valugerdi M; Griskevicius L; Nilsson C; Remberger M; Aschan J; Concha H; Gaughan U; Hassan M
Exp Hematol; 2006 Jan; 34(1):115-21. PubMed ID: 16413398
[TBL] [Abstract][Full Text] [Related]
2. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
[TBL] [Abstract][Full Text] [Related]
3. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers.
van Pel M; van Breugel DW; Vos W; Ploemacher RE; Boog CJ
Bone Marrow Transplant; 2003 Jul; 32(1):15-22. PubMed ID: 12815473
[TBL] [Abstract][Full Text] [Related]
4. Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers.
van Pel M; van Breugel DW; Vos W; Ploemacher RE; Boog CJ
Bone Marrow Transplant; 2004 Jan; 33(2):153-9. PubMed ID: 14661037
[TBL] [Abstract][Full Text] [Related]
5. Growth of human hematopoietic cells in immunodeficient mice conditioned with cyclophosphamide and busulfan.
Basch RS; Quito FL; Beh J; Hirst JA
Stem Cells; 1997; 15(4):314-23. PubMed ID: 9253116
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
7. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.
Köpf-Maier P
In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471
[TBL] [Abstract][Full Text] [Related]
8. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.
Sjöö F; Aschan J; Barkholt L; Hassan Z; Ringdén O; Hassan M
Bone Marrow Transplant; 2003 Aug; 32(4):349-54. PubMed ID: 12900770
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.
Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S
Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251
[TBL] [Abstract][Full Text] [Related]
10. Effect of Withania somnifera on cytokine production in normal and cyclophosphamide treated mice.
Davis L; Kuttan G
Immunopharmacol Immunotoxicol; 1999 Nov; 21(4):695-703. PubMed ID: 10584205
[TBL] [Abstract][Full Text] [Related]
11. Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma.
Reichardt W; Juettner E; Uhl M; Elverfeldt DV; Kontny U
Invest Radiol; 2009 May; 44(5):298-303. PubMed ID: 19346963
[TBL] [Abstract][Full Text] [Related]
12. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.
Sadeghi B; Jansson M; Hassan Z; Mints M; Hägglund H; Abedi-Valugerdi M; Hassan M
Bone Marrow Transplant; 2008 May; 41(10):895-904. PubMed ID: 18223695
[TBL] [Abstract][Full Text] [Related]
13. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
Fichtner I; Becker M; Baumgart J
Eur J Cancer; 2003 Apr; 39(6):801-7. PubMed ID: 12651206
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Munkelt D; Koehl U; Kloess S; Zimmermann SY; Kalaäoui RE; Wehner S; Schwabe D; Lehrnbecher T; Schubert R; Kreuter J; Klingebiel T; Esser R
Cancer Chemother Pharmacol; 2008 Oct; 62(5):821-30. PubMed ID: 18246351
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution.
Bouazzaoui A; Dickhöfer S; Kreuz M; Huber E; Holler E; Wolff D
Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):158-64. PubMed ID: 24588615
[TBL] [Abstract][Full Text] [Related]
17. Application of chimerism-based drug-induced tolerance to rat into mouse xenotransplantation.
Tomita Y; Shimizu I; Iwai T; Zhang QW; Okano S; Kajiwara T; Onzuka T; Tominaga R
Scand J Immunol; 2006 Oct; 64(4):392-7. PubMed ID: 16970680
[TBL] [Abstract][Full Text] [Related]
18. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
[TBL] [Abstract][Full Text] [Related]
19. Role of the cytokine profiles produced by invariant natural killer T cells in the initial phase of cyclophosphamide-induced tolerance.
Onzuka T; Tomita Y; Shimizu I; Okano S; Yamada H; Yoshikai Y; Tominaga R
Transplantation; 2008 Nov; 86(9):1301-10. PubMed ID: 19005413
[TBL] [Abstract][Full Text] [Related]
20. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
